RedHill Biopharma Acquires Rights to Two Ferring GI Drugs

Key Facts

1RedHill Biopharma acquired exclusive commercialization rights for Rebyota and Clenpiq from Ferring.

2The $12 million upfront payment was fully funded by the previously announced $18 million divestment of Talicia.

3The two acquired GI drugs generated approximately $37.5 million in net sales during 2025.

In a move reflecting a strategic shift in the specialty healthcare sector, RedHill Biopharma announced the acquisition of exclusive commercialization rights for Rebyota and Clenpiq from Ferring Pharmaceuticals. This transaction is part of a strategic repositioning to replace previous assets with higher-revenue products and expand commercial scale within the gastrointestinal market. The deal was secured with a $12 million upfront payment, fully funded by the previously announced $18 million divestment of the Talicia asset.

Financial data highlights the strength of the acquired assets, as the two drugs generated approximately $37.5 million in combined net sales during 2025, significantly improving the company's liquidity profile. According to analyst reports, Rebyota alone generated $16.9 million in U.S. sales last year, while Clenpiq maintains extensive access across millions of Medicare Part D beneficiaries, bolstering the outlook for future revenue growth.

Regarding market performance, current price levels for RDHL were unavailable at the time of this report on September 1, 2026, though investors are monitoring the impact of this strategic pivot on the company's balance sheet. Looking at the economic calendar, market participants are weighing broader consumer trends following the US CB Consumer Confidence reading of 89.4 on August 25, 2026, as a gauge for healthcare spending sentiment.